Pomerantz LLP opens investor inquiry into Elicio Therapeutics (NASDAQ: ELTX)
An investor inquiry into claims against Elicio Therapeutics, Inc. (NASDAQ: ELTX) is underway, Pomerantz LLP disclosed, with the firm directing shareholders to contact attorney Danielle Peyton. The release did not name specific allegations or a period under review.
Key takeaways
- Pomerantz LLP disclosed it has opened an investor inquiry into claims against Elicio Therapeutics, Inc. (NASDAQ: ELTX).
- The firm's release did not name any specific allegations, monetary figures, or a period under review.
- Pomerantz LLP directed shareholders to contact attorney Danielle Peyton for information.
- Investors can reach Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980.
- The disclosure was issued from New York, and Elicio Therapeutics trades on the Nasdaq exchange under the ticker ELTX.
An investor inquiry into claims against Elicio Therapeutics, Inc. (NASDAQ: ELTX) is underway, Pomerantz LLP disclosed, with the firm directing shareholders to contact attorney Danielle Peyton. The release did not name specific allegations or a period under review.
What the firm announced
Pomerantz LLP said it is investigating claims on behalf of investors of Elicio Therapeutics. The release offered no detail on the timeline or scope of the inquiry. Elicio Therapeutics trades on the Nasdaq exchange under the ticker ELTX.
How to reach the firm
Investors seeking information were directed to Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980, the release shows. The firm issued the disclosure from New York.
Editor's note: The source release provided no allegations, monetary figures, or review period. This article reflects only the facts disclosed.